PDX may be used as an ideal model for advanced pancreatic cancer

Pancreatic ductal adenocarcinoma is a very high mortality rate of malignant cancer, a disease that has the ability to aggressive and fast-moving, so the pancreatic ductal adenocarcinoma is still a very difficult to treat clinical disease. If you can on the incidence and mechanisms of invasion and metastasis of pancreatic ductal adenocarcinoma have a more in-depth understanding, it will greatly promote the development of drugs and treatments, but there is still a lack of late-stage cancer to represent an ideal model of disease. In addition, PDX animal models before clinical trials for cancer among patients with carcinoma in situ molecular similarity how are still unknown.
To find potential metastatic pancreatic cancer progression driving molecule, scientists from the United States and Spain, in situ tumors from an autopsy project, metastatic tumor and normal samples (peripheral blood) were full-exon, and they also constructed corresponding PDX model, also we were sequenced, and compared with the patient's tumor.
 After the sequence data from three patients were analyzed, the researchers found that the presence of 160 single nucleotide mutation in each tumor sample average, the majority of mutations are present in each patient's tumor and metastases in situ, more It is important that most of these mutations are retained in the PDX model.
 Based on in-situ tumors and metastases mutation rate, the researchers propose possible cloning evolution model that exists in the function mutations affect some important oncogenes, such as KRAS, TP53, and SMAD4, these oncogenes are tumorigenesis and metastasis plays an important role.